Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DSGNNASDAQ:HUMANASDAQ:KPTINASDAQ:OCGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDSGNDesign Therapeutics$3.21-10.1%$3.95$2.60▼$7.77$182.23M1.77187,721 shs68,723 shsHUMAHumacyte$1.87+8.1%$1.86$1.15▼$9.97$290.07M1.643.71 million shs8.56 million shsKPTIKaryopharm Therapeutics$4.85-1.4%$5.46$3.51▼$17.85$41.56M0.3382,759 shs71,800 shsOCGNOcugen$0.69-1.1%$0.67$0.52▼$2.06$202.84M4.214.49 million shs1.72 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDSGNDesign Therapeutics-10.08%-2.79%-1.23%-19.14%-28.51%HUMAHumacyte+8.09%+53.28%+25.50%-52.30%-70.87%KPTIKaryopharm Therapeutics-1.42%-20.62%+15.20%-46.97%-70.34%OCGNOcugen-1.12%+4.91%+3.47%-1.15%-59.14%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDSGNDesign Therapeutics0.737 of 5 stars2.00.00.00.01.72.50.6HUMAHumacyte2.747 of 5 stars3.52.00.00.02.53.30.6KPTIKaryopharm Therapeutics3.7717 of 5 stars3.50.00.04.62.32.50.6OCGNOcugen1.1179 of 5 stars3.51.00.00.01.90.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDSGNDesign Therapeutics 2.00Hold$4.0024.61% UpsideHUMAHumacyte 3.00Buy$11.71526.43% UpsideKPTIKaryopharm Therapeutics 3.00Buy$43.20790.72% UpsideOCGNOcugen 3.00Buy$6.00763.81% UpsideCurrent Analyst Ratings BreakdownLatest KPTI, DSGN, HUMA, and OCGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025HUMAHumacyteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$4.005/14/2025HUMAHumacyteBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $14.005/13/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.005/13/2025KPTIKaryopharm TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$34.00 ➝ $33.005/13/2025KPTIKaryopharm TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$5.00 ➝ $10.005/13/2025KPTIKaryopharm TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$54.00 ➝ $42.005/12/2025OCGNOcugenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $7.005/12/2025OCGNOcugenChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.003/26/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.003/12/2025HUMAHumacyteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/7/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.00(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDSGNDesign TherapeuticsN/AN/AN/AN/A$4.96 per shareN/AHUMAHumacyte$1.57M184.76N/AN/A$0.13 per share14.38KPTIKaryopharm Therapeutics$145.24M0.29N/AN/A($1.47) per share-3.30OCGNOcugen$4.52M44.86N/AN/A$0.16 per share4.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDSGNDesign Therapeutics-$66.86M-$0.99N/AN/AN/AN/A-18.01%-17.38%N/AHUMAHumacyte-$110.78M-$1.26N/AN/AN/AN/A-942.81%-93.82%N/AKPTIKaryopharm Therapeutics-$143.10M-$15.29N/AN/AN/A-52.62%N/A-39.58%N/AOCGNOcugen-$63.08M-$0.19N/AN/AN/A-532.51%-154.75%-90.79%N/ALatest KPTI, DSGN, HUMA, and OCGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025DSGNDesign Therapeutics-$0.28-$0.31-$0.03-$0.31N/AN/A5/13/2025Q1 2025HUMAHumacyte-$0.19-$0.10+$0.09$0.28$0.46 million$0.52 million5/12/2025Q1 2025KPTIKaryopharm Therapeutics-$4.21-$2.77+$1.44-$2.77$35.12 million$30.02 million5/9/2025Q1 2025OCGNOcugen-$0.06-$0.05+$0.01-$0.05N/A$1.48 million3/28/2025Q4 2024HUMAHumacyte-$0.23-$0.16+$0.07-$0.16$0.64 million$7.23 million3/10/2025Q4 2024DSGNDesign Therapeutics-$0.28-$0.24+$0.04-$0.24N/AN/A3/5/2025Q4 2024OCGNOcugen-$0.05-$0.05N/A-$0.05$0.30 million$0.76 million2/19/2025Q4 2024KPTIKaryopharm Therapeutics-$3.90-$3.60+$0.30-$0.24$30.29 million$30.54 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDSGNDesign TherapeuticsN/AN/AN/AN/AN/AHUMAHumacyteN/AN/AN/AN/AN/AKPTIKaryopharm TherapeuticsN/AN/AN/AN/AN/AOCGNOcugenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDSGNDesign TherapeuticsN/A34.6134.61HUMAHumacyteN/A1.101.10KPTIKaryopharm TherapeuticsN/A1.702.93OCGNOcugen0.042.582.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDSGNDesign Therapeutics56.64%HUMAHumacyte44.71%KPTIKaryopharm Therapeutics66.44%OCGNOcugen10.27%Insider OwnershipCompanyInsider OwnershipDSGNDesign Therapeutics31.20%HUMAHumacyte11.20%KPTIKaryopharm Therapeutics2.98%OCGNOcugen4.29%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDSGNDesign Therapeutics4056.77 million38.96 millionOptionableHUMAHumacyte150155.12 million111.76 millionOptionableKPTIKaryopharm Therapeutics3808.57 million122.72 millionOptionableOCGNOcugen80292.03 million278.82 millionOptionableKPTI, DSGN, HUMA, and OCGN HeadlinesRecent News About These CompaniesThe Analyst Verdict: Ocugen In The Eyes Of 5 ExpertsMay 14 at 9:45 PM | nasdaq.comOcugen (NASDAQ:OCGN) Price Target Cut to $7.00 by Analysts at HC WainwrightMay 14 at 10:07 AM | marketbeat.comOcugen's (OCGN) "Buy" Rating Reiterated at Chardan CapitalMay 14 at 8:24 AM | marketbeat.comHC Wainwright Has Lowered Expectations for Ocugen (NASDAQ:OCGN) Stock PriceMay 14 at 1:57 AM | americanbankingnews.comOcugen (NASDAQ:OCGN) Releases Earnings Results, Beats Estimates By $0.01 EPSMay 13 at 8:14 AM | marketbeat.comOcugen Reports Progress in Q1 2025 with Advancements in Gene TherapyMay 13 at 5:39 AM | msn.com1OCGN : The Analyst Verdict: Ocugen In The Eyes Of 5 ExpertsMay 13 at 5:39 AM | benzinga.comOcugen, Inc. (NASDAQ:OCGN) Q1 2025 Earnings Call TranscriptMay 10, 2025 | msn.comOcugen Stock Rises On Better-Than-Feared Q1 Loss: Retail Turns BullishMay 9, 2025 | msn.comOcugen, Inc. (OCGN) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comOcugen Provides Business Update with First Quarter 2025 Financial ResultsMay 9, 2025 | globenewswire.comA Look at Ocugen's Upcoming Earnings ReportMay 9, 2025 | benzinga.comOcugen (OCGN) Projected to Post Earnings on FridayMay 6, 2025 | marketbeat.comOcugen to Host Q1 2025 Earnings Call and Business Update on May 9May 5, 2025 | msn.comOCUGEN Earnings Preview: Recent $OCGN Insider Trading, Hedge Fund Activity, and MoreMay 2, 2025 | nasdaq.comOcugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial ResultsMay 2, 2025 | globenewswire.comOcugen to Showcase Gene Therapy Advances at Upcoming Ophthalmology ConferencesMay 2, 2025 | msn.comOcugen to Showcase Gene Therapy Advances at Upcoming Ophthalmology ConferencesMay 2, 2025 | msn.comOcugen to Present at Eyecelerator Conference May 2025May 1, 2025 | tipranks.comOcugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World CongressApril 29, 2025 | globenewswire.comRenaissance Technologies LLC Invests $1.68 Million in Ocugen, Inc. (NASDAQ:OCGN)April 29, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumGold Rally Continues: These 3 Mining Stocks Are Likely to BenefitBy Chris Markoch | April 16, 2025View Gold Rally Continues: These 3 Mining Stocks Are Likely to BenefitAMD’s AI-Powered Stock Price Rally Just Shifted GearsBy Thomas Hughes | May 14, 2025View AMD’s AI-Powered Stock Price Rally Just Shifted Gears2 Healthcare Recession-Resistant Stocks Unaffected by TariffsBy Jea Yu | April 15, 2025View 2 Healthcare Recession-Resistant Stocks Unaffected by TariffsKPTI, DSGN, HUMA, and OCGN Company DescriptionsDesign Therapeutics NASDAQ:DSGN$3.21 -0.36 (-10.08%) As of 05/14/2025 04:00 PM EasternDesign Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.Humacyte NASDAQ:HUMA$1.87 +0.14 (+8.09%) As of 05/14/2025 04:00 PM EasternHumacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.Karyopharm Therapeutics NASDAQ:KPTI$4.85 -0.07 (-1.42%) As of 05/14/2025 04:00 PM EasternKaryopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.Ocugen NASDAQ:OCGN$0.69 -0.01 (-1.12%) As of 05/14/2025 04:00 PM EasternOcugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start AMD’s AI-Powered Stock Price Rally Just Shifted Gears Oklo Reaches Critical Mass, Atomic Upside Still Available Is Verizon a Buy? Q1 Results and Solid Dividend Make Bullish Case Carnival's Comeback: Is the Stock Set for a Profitable Journey? 5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
